Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients (Q38798383)

6 September 2017

Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients (English)

1 reference

6 September 2017

H Shomura

1

1 reference

6 September 2017

S Shichijo

2

1 reference

6 September 2017

S Matsueda

3

1 reference

6 September 2017

T Kawakami

4

1 reference

6 September 2017

Y Sato

5

1 reference

6 September 2017

S Todo

6

1 reference

6 September 2017

K Itoh

7

1 reference

6 September 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

6 September 2017

9

1 reference

British Journal of Cancer

inferred from page(s)

published in

1 reference

6 September 2017

90

1 reference

6 September 2017

8

1 reference

6 September 2017

1563-1571

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601728

6 September 2017

0 references

cites work

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Molecular basis of T cell-mediated recognition of pancreatic cancer cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Epidermal growth factor-related peptides and their receptors in human malignancies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

IgG reactive to CTL‐directed epitopes of self‐antigens is either lacking or unbalanced in atopic dermatitis patients

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Expression of growth-factor receptors in normal and regenerating human periodontal cells.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409701

Immune responses to all ErbB family receptors detectable in serum of cancer patients

31 August 2018

1 reference

12 December 2020

Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals

1 reference

12 December 2020

Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients

1 reference

12 December 2020

Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers

1 reference

12 December 2020

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601728

1 reference

Dimensions Publication ID

6 September 2017

0 references

1 reference

6 September 2017

1 reference